Oncaspar

RSS

pegaspargase

Authorised
This medicine is authorised for use in the European Union.

Overview

Oncaspar is a cancer medicine used in adults and children to treat acute lymphoblastic leukaemia (ALL), a cancer of white blood cells called lymphoblasts. Oncaspar is used in combination with other cancer medicines.

It contains the active substance pegaspargase.

This EPAR was last updated on 25/01/2023

Authorisation details

Product details
Name
Oncaspar
Agency product number
EMEA/H/C/003789
Active substance
pegaspargase
International non-proprietary name (INN) or common name
pegaspargase
Therapeutic area (MeSH)
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anatomical therapeutic chemical (ATC) code
L01XX24
Publication details
Marketing-authorisation holder
Les Laboratoires Servier
Revision
16
Date of issue of marketing authorisation valid throughout the European Union
14/01/2016
Contact address

Les laboratoires Servier
50, rue Carnot
F-92284 Suresnes Cedex
France

Product information

13/09/2022 Oncaspar - EMEA/H/C/003789 - II/0048

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.

Assessment history

How useful was this page?

Add your rating
Average
2 ratings
1 rating
2 ratings